B7-1

Ocean Biomedical (NASDAQ: OCEA) Shares Detailed Research Data on Anti-Tumor Pathway Discoveries and Their Potential for Treatment of Non-Small Cell Lung Cancer, Metastatic Melanoma, and Glioblastoma by Scientific Co-founder

Retrieved on: 
Thursday, March 9, 2023
Ocean Biomedical, Colorectal cancer, Neoplasm, Breast cancer, Survival, Ovarian cancer, Skin cancer, Brown University, Cancer, Biology, HIV disease progression rates, Research, Patient, PTEN, Fibrosis, ICOS, Lung cancer, Prostate cancer, Kidney cancer, CTLA4, Antibody, Cluster, Apoptosis, Journal, PD-1, RI, NSCLC, CD28, B7-1, Composition, Prognosis, B7-2, Pharmaceutical industry, Medical imaging, Vaccine, Melanoma, Medicine, Immunology, CHI3L1, Frontiers, MD, Glioblastoma

In his talk, Dr. Elias focused on his lab’s groundbreaking work on understanding the development and progression of lung cancer, especially the role of Chitinase 3-like-1 (CHI3L1).

Key Points: 
  • In his talk, Dr. Elias focused on his lab’s groundbreaking work on understanding the development and progression of lung cancer, especially the role of Chitinase 3-like-1 (CHI3L1).
  • He also shared details of his novel therapeutic discoveries that show the efficacy of monospecific and bispecific antibodies against CHI3L1 and PD-1 as therapies for non-small cell lung cancer, and glioblastoma multiforme.
  • Ocean Biomedical is currently working to move these antibody therapeutic discoveries towards Phase 1 clinical trials.
  • In his recent talk, Dr. Elias shared details of his team’s discoveries of the role CHI3L1 in regulating primary and metastatic lung cancer, glioblastoma multiforme, and broader oncogenic pathways.

Ocean Biomedical and Aesther Healthcare Acquisition Corp. Announce Publication of Discovery Data for a Major Anti-Tumor Pathway in Malignant Melanoma and Other Cancers

Retrieved on: 
Monday, January 30, 2023
B7-1, Antibody, Fibrosis, Metastasis, Skin cancer, Melanoma, Cluster, Journal, PD-1, Large-cell lung carcinoma, Cancer, Biology, NSCLC, B7-2, RI, Outline, Lung, PTEN, Patient, ICOS, CD28, Apoptosis, Glioblastoma, CTLA4, Neoplasm, Research, Vaccine, Medical imaging, Immunology, CHI3L1, Medicine, Frontiers

Providence, RI and New York, NY, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA) announced today the discovery of a second major anti-tumor pathway and therapeutic approach that targets CTLA-4, inhibiting the metastasis of malignant melanoma cells to the lung using a novel bispecific antibody approach. This major regulating mechanism discovery, recently published in Frontiers in Immunology, by Ocean Biomedical’s Scientific Co-founder and Brown University’s Emeritus Dean of Medicine and Biological Sciences, Dr. Jack A. Elias, builds on his team’s prior discoveries that target Chitinase 3-like-1 (CHI3LI) and its role in inhibiting T-cell proliferation. Additionally, this promising research reveals a third anti-tumor pathway targeting T-cell co-stimulation using the inducible co-stimulator (ICOS) and its ligand ICOSL, and Cluster of Differentiation 28 (CD28) and its ligands B7-1 and B7-2. Ocean Biomedical’s novel approach to tumor suppression, focused on controlling CHI3LI, other immune checkpoint inhibitors, and T-cell co-stimulators, has potential application for tumor suppression across multiple cancer pathways.

Key Points: 
  • Ocean Biomedical’s novel approach to tumor suppression, focused on controlling CHI3LI, other immune checkpoint inhibitors, and T-cell co-stimulators, has potential application for tumor suppression across multiple cancer pathways.
  • “If you control CH3L1, you don’t just control one anti-cancer pathway, you simultaneously control many anti-cancer pathways.
  • Malignant melanoma, a very serious skin cancer with a 22.5% five-year survival for patients with Stage IV disease, can metastasize to other organs.
  • We look forward to working with Ocean Biomedical to bring all of these therapies to patients, for the long-term shareholder value and the continued advancement of medical science.”